Similarly, in the US, during 2014–2015, data from a large cohort of 1,202,596 patients showed that less than 12% used either SGLT2is or GLP-1 RAs for T2D management (Weng et al., 2019). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.